Expiring patents on major brand name drugs, particularly bipolar treatments and other prescriptions for central nervous system disorders, may cost $65 billion in lost sales by 2019, a new study shows.
Expiring patents on major brand name drugs, particularly bipolar treatments and other prescriptions for central nervous system disorders, may cost $65 billion in lost sales by 2019, a new study shows.